TY - JOUR T1 - Severe Neuro-COVID is associated with peripheral immune signatures, autoimmunity and signs of neurodegeneration: a prospective cross-sectional study JF - medRxiv DO - 10.1101/2022.02.18.22271039 SP - 2022.02.18.22271039 AU - Manina M. Etter AU - Tomás A. Martins AU - Laila Kulsvehagen AU - Elisabeth Pössnecker AU - Wandrille Duchemin AU - Sabrina Hogan AU - Gretel Sanabria-Diaz AU - Jannis Müller AU - Alessio Chiappini AU - Jonathan Rychen AU - Noëmi Eberhard AU - Lester Melie-Garcia AU - Emanuela Keller AU - Ilijas Jelcic AU - Hans Pargger AU - Martin Siegemund AU - Jens Kuhle AU - Johanna Oechtering AU - Caroline Eich AU - Alexandar Tzankov AU - Matthias S. Matter AU - Özgür Yaldizli AU - Johanna M. Lieb AU - Marios-Nikos Psychogios AU - Caroline M. Berkemeier AU - Karoline Leuzinger AU - Hans H. Hirsch AU - Cristina Granziera AU - Anne-Katrin Pröbstel AU - Gregor Hutter Y1 - 2022/01/01 UR - http://medrxiv.org/content/early/2022/03/02/2022.02.18.22271039.abstract N2 - Importance Growing evidence suggests that coronavirus disease 2019 (COVID-19) is associated with neurological sequelae. However, the underlying pathophysiological mechanisms resulting in central nervous system (CNS) derogation remain unclear.Objective To identify severity-dependent immune mechanisms in the cerebrospinal fluid (CSF) and plasma of COVID-19 patients and their association with brain imaging alterations.Design Prospective cross-sectional cohort study.Setting This study was performed from August 2020 to April 2021. Participants were enrolled in the outpatient clinics, hospital wards and intensive care units (ICU) of two clinical sites in Basel and Zurich, Switzerland.Participants Age >18 years and a positive SARS-CoV-2 test result were inclusion criteria. Potentially matching individuals were identified (n=310), of which 269 declined to participate and 1 did not match inclusion criteria. Paired CSF and plasma samples, as well as brain images, were acquired. The COVID-19 cohort (n=40; mean [SD] age, 54 [20] years; 17 women (42%)) was prospectively assorted by neurological symptom severity (classes I, II and III). Age/sex-matched inflammatory (n=25) and healthy (n=25) CSF and plasma control samples were obtained. For volumetric brain analysis, a healthy age/sex-matched control cohort (n=36) was established.Exposures Lumbar puncture, blood sampling and cranial MRI and/or CT.Main outcomes and measures Proteomics, standard parameters and antibody profiling of paired CSF and plasma samples in COVID-19 patients and controls. Brain imaging and gray matter volumetric analysis in association with biomarker profiles. Follow-up after 10-months.Results COVID-19 patients displayed a plasma cytokine storm but a non-inflammatory CSF profile. Class III patients displayed signs of blood-brain barrier (BBB) impairment and a polyclonal B cell response targeting self- and non-self antigens. Decreased regional brain volumes were present in COVID-19 patients and associated with specific CSF and plasma parameters.Conclusion and relevance Neuro-COVID class III patients had a strong, peripheral immune response resulting in (1) BBB impairment (2) ingress of (auto-)antibodies, (3) microglia activation and neuronal damage signatures. Our data point towards several potentially actionable targets that may be addressed to prevent COVID-19-related neurological sequelae.Trial registration The trial (NCT04472013) was registered on clinicaltrials.gov.Question Does a severity-dependent pattern of immune mechanisms exist in the cerebrospinal fluid (CSF) and plasma of COVID-19 patients and are these associated with clinical and brain imaging findings?Findings Neuro-COVID patients display a robust class III-specific peripheral immune response resulting in (1) blood-brain barrier (BBB) impairment, (2) ingress of (auto-)antibodies, (3) microglia activation and neuronal damage signatures. Integration of MRIs, brain volumetry and proteomics identified biomarkers associated with regional brain volume loss in severe Neuro-COVID.Meaning We provide a multidimensional framework of mechanisms associated with severe Neuro-COVID and present possible targets to prevent COVID-19-related neurological sequelae.Competing Interest StatementI.J. has received speaker honoraria or unrestricted grants from Biogen Idec and Novartis and has served as an advisor for Alexion, Biogen, Bristol Myers Squibb, Celgene, Janssen-Cilag, Neuway, Merck, Novartis, Roche and Sanofi Genzyme; none of these are related to this study. G.H. has equity in and is a co-founder of Incephalo Inc. A-K.P. has received speaker honoraria or research/travel support from Roche and Biogen all used for research.Funding StatementThe study was funded by the BOTNAR Fast Track Call foundation grant (FTC-2020-10) awarded to G.H., M.M. and A.T. The Neuroimmunology and Multiple Sclerosis Research Section, Department of Neurology, University Hospital Zurich, Zurich, Switzerland, with support by the Clinical Research Priority Program (CRPP) MS as well as the CRPP Precision-MS of the University Zurich, Zurich, Switzerland. The work was partly supported by the Swiss National Science Foundation (grant number: 4078P0_198345, title: Protective and pathogenic T cell immunity during SARS-CoV-2 infection) and the Loop Zurich, COVID-19 project (SARS-CoV-2-induced immune alterations and their role in post-COVID syndrome). The study was also funded by the Propatient Foundation, the Swiss National Science Foundation, and the Goldschmidt-Jacobson Foundation grants awarded to A-K.P.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Etikkommission Nordwest- und Zentralschweiz (EKNZ 2020-01503) gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript ER -